VCYT Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
150.3M
+8.1%
139.1M
-1.1%
140.6M
+6.6%
131.9M
+1.3%
130.2M
Cost of Revenue
41.8M
+10.2%
37.9M
-1.9%
38.7M
-4.7%
40.6M
+0.5%
40.4M
Gross Profit
108.5M
+7.3%
101.2M
-0.8%
102.0M
+11.7%
91.3M
+1.7%
89.8M
Operating Expenses
85.6M
+9.0%
78.5M
+21.2%
64.8M
-5.2%
68.3M
-28.1%
95.0M
R&D
29.4M
+8.7%
27.1M
+30.0%
20.8M
+30.5%
16.0M
-1.7%
16.3M
SG&A
55.7M
+9.6%
50.8M
+17.4%
43.3M
-16.3%
51.7M
-10.3%
57.6M
Operating Income
23.0M
+1.5%
22.6M
-39.1%
37.2M
+62.1%
22.9M
+535.6%
-5268000
EBITDA
27.8M
-0.9%
28.1M
-33.9%
42.5M
+50.6%
28.2M
+36.1%
20.7M
Net Income
25.5M
-11.2%
28.7M
-30.2%
41.1M
+115.0%
19.1M
+2052.8%
-980000
EPS (Basic)
$0.32
-11.1%
$0.36
-30.8%
$0.52
+116.7%
$0.24
+2500.0%
$-0.01
EPS (Diluted)
$0.31
-11.4%
$0.35
-28.6%
$0.49
+104.2%
$0.24
+2500.0%
$-0.01
Shares (Diluted)
82.1M
+0.9%
81.3M
-3.4%
84.2M
+5.6%
79.7M
+1.7%
78.4M
Veracyte (VCYT) โ€” Financials